Elsevier Announces Publication of Five New Books on Virology Including Second Edition of Adenoviral Vectors for Gene Therapy

Fully Updated Edition Provides the Latest Coverage of Gene Delivery Vehicles Based on the Adenovirus, Now Emerging as an Important Tool in Gene Therapy

CAMBRIDGE, MA --(Marketwired - April 29, 2016) - Elsevier, a world-leading provider of scientific, technical and medical information products and services, today announced the publication of five new virology books including the second edition of the detailed, comprehensive resource Adenoviral Vectors for Gene Therapy, edited by David Curiel. This book covers the gene delivery vehicles based on the adenovirus, now emerging as an important tool in gene therapy. It highlights their potential uses for the treatment of disease with information on the construction, propagation and purification of adenoviral vectors.

The new edition provides complete coverage of the basic biology of adenoviruses. It introduces common strategies for the development of adenoviral vectors, along with cutting-edge methods for their improvement, and demonstrates noninvasive imaging of adenovirus-mediated gene transfer.

The book also discusses the utility of adenoviral vectors in animal disease models, and considers Federal Drug Administration regulations for human clinical trials.

Learn more about adenoviral vectors in this chapter on transductional targeting

Dr. Curiel is the Director of the Cancer Biology Division of the Department of Radiation Oncology at Washington University School of Medicine. His scientific training includes tenure at the National Institutes of Health in Bethesda, Maryland at the Pulmonary Branch of the Heart and Lung, and Blood Institute (NHLBI), and a fellowship in Biotechnology at the National Cancer Institute, Navy Medical Oncology Branch. In addition to his current role as Director of the Cancer Biology Division, he is Director of the Biologic Therapeutics Center.

In order to meet content needs in virology, Elsevier uses proprietary tools to identify the gaps in coverage of the topics. Editorial teams strategically fill those gaps with content written by key influencers in the field, giving students, faculty and researchers the content they need to answer challenging questions and improve outcomes. These new books, which will educate the next generation of virologists and provide critical foundational content for information professionals, are key examples of how Elsevier is enabling science to drive innovation.

E-book review copies of the new books are available to credentialed journalists upon request. Contact Robin Hayward at R.Hayward@elsevier.com.

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions - among them ScienceDirect, Scopus, Elsevier Research Intelligence and ClinicalKey - and publishes over 2,500 journals, including The Lancet and Cell, and more than 33,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries, www.elsevier.com.